Webinar Technology

Harnessing in situ transcriptomics to reveal complex tissue architecture at single-cell resolution

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Harnessing in situ transcriptomics to reveal complex tissue architecture at single-cell resolution

02 August 2018

12:00 p.m. ET

Register to watch recording


Sequencing of RNA (RNASeq) can provide a trove of useful information for quantification and characterization of the transcriptome. During bulk sequencing, however, spatial and cellular heterogeneity information is lost. Enter single-cell–level analysis, which can provide unprecedented detail on cellular diversity in development, health, and disease. This emerging area of spatial transcriptomics aims to map a single-cell–level molecular atlas of human tissues in situ. However, mapping entire tissue areas at single-cell quantitative resolution presents significant challenges for imaging and data analysis. In this webinar, efforts to develop large-scale in situ transcriptomics will be described, using the mouse brain as a model system for mapping the molecular diversity of neuronal and glial cell types. The experimental workflow includes automated tissue processing, imaging and analysis for large-scale multiplex mapping, and quantification of gene expression across brain regions in situ at single-cell resolution. The technology that makes this high-resolution mapping possible will be described and compared with other current methods.

During the webinar, the speakers will:

  • Describe the power and usefulness of in situ transcriptomics
  • Discuss the application of this technology to large-scale tissue mapping in the mouse brain
  • Explain how in situ transcriptomics (using RNAScope technology) can complement RNASeq and single-cell RNASeq
  • Answer audience questions during the live broadcast!

To learn more about products or technologies related to this webinar, go to http://rna.acdbio.com/transcriptomics.

This webinar will last for approximately 60 minutes.

Speaker bios

Omer Bayraktar, Ph.D.

Wellcome Sanger Institute
Hinxton, U.K.

Dr. Bayraktar is a new group leader at the Wellcome Sanger Institute in Hinxton, United Kingdom. He is interested in large-scale mapping of cellular diversity across human tissues with a focus on nervous system development and disease. He was a postdoctoral fellow with David Rowitch at the University of California, San Francisco and the University of Cambridge, where he developed a high-content in situ transcriptomic pipeline for mapping large tissue areas. He used this approach to elucidate the heterogeneity of astroglial cells across multiple layers and different areas of the mammalian cerebral cortex. He completed his Ph.D. with Chris Doe at the Howard Hughes Medical Institute, where he characterized combinatorial temporal patterning programs in neural stem cells that expand cellular diversity.

Xiao-Jun Ma, Ph.D.

Advanced Cell Diagnostics
San Francisco, CA

Dr. Xiao-Jun Ma is chief scientific officer at Advanced Cell Diagnostics (ACD), a Bio-Techne brand company developing advanced tissue biomarker analysis technologies. At ACD, he led R&D for RNAscope and BaseScope technologies for highly sensitive and specific RNA in situ hybridization used in RNA analysis with cellular resolution. Before joining ACD, he was vice president of R&D/Biostatistics at Biotheranostics, where he directed the development of prognostic and predictive gene signature assays for breast and prostate cancer, and a gene expression classifier for cancers of unknown primary. Prior to his employment at Biotheranostics, he worked at Johnson & Johnson and Monsanto/Searle (now Pfizer) on new drug target discovery. Dr. Ma received his Ph.D. in biochemistry from the University of Iowa.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here